Mischele Hoffman is humble. With a background that includes 12 years in sales, two years administering a nonprofit organization for people with disabilities and a master's degree in health sciences, not to mention a highly successful year with Eisai Pharmaceuticals, it would be easy for her not to be. But Hoffman's patient-focused approach to selling and the match she's found in a company that also places a high value on patient advocacy has proved to be a good combination.
Mischele Hoffman is humble. With a background that includes 12 years in sales, two years administering a nonprofit organization forpeople with disabilities and amaster's degree in health sciences, not to mention a highly successful year with Eisai Pharmaceuticals, it would be easy for her not to be. But Hoffman's patient-focused approach to selling and the match she's found in a company that also places a high value on patient advocacy has proved to be a good combination.
In addition to staying on top of a four-week call cycle and preparing for her March wedding, Hoffman volunteers at an Alzheimer's care facility. (One of her products is an Alzheimer's medication.) Her experience there and as a former human services professional makes a difference. "My perspective is different," she said. "The true compassion for the patient coming out lends more credibility; it's not a hard sell."
She pointed out: "If we continually focus on just the numbers - you know, 'What's his favorite kind of chocolate?' - we lose sight of the real goal, and you have a tendency to get burned out with that approach."
And Hoffman wouldn't dream of it. "I know that I have a message to give them and it's important. And when I do finally get their time, I'm going to make it worth their while and mine. That's what keeps me going."
Hoffman's advice for new reps is to believe in their role as educator. "The best thing that you can bring to this job is a fresh, sincere approach," she said. "And a true belief in yourself and what you do."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Roche Inks Deal to Acquire Poseida Therapeutics
December 2nd 2024Under terms of the deal, Roche will gain access to Poseida’s pipeline, including P-BCMA-ALLO1, an allogeneic CAR T-cell therapy for multiple myeloma, and P-CD19CD20-ALLO1, a dual CAR T-cell therapy in early trials for B-cell malignancies and autoimmune diseases.